Monthly Roundup

A session on next-generation hemophilia gene therapy, discussed strategies to address challenges like durability, variability, and predictability of factor expression. Advances include modifications to AAV vectors, such as engineered capsids, optimized transgene cassettes, and the exploration of alternative target cells like liver sinusoidal endothelial cells. Other strategies involve lentiviral systems targeting platelets, monocytes, or plasma cells. Clinical trials are also testing CRISPR-Cas9 gene editing for hemophilia B, where lipid nanoparticles deliver CRISPR and AAV vectors to insert the factor IX gene. Non-viral approaches, such as the piggyBac transposon system, use lipid nanoparticles to integrate genes into the host genome.

These methods may benefit pediatric patients and those with proliferating liver cells but require careful management of off-target effects and integration risks. These developments expand patient eligibility and improve treatment precision, signaling significant progress in hemophilia gene therapy.